Financial team, us executive good Caren our Thank and of and are Chief Erick Strategy today Deardorf. Chief morning, Burkly; Commercial Earnings Officer, our Thanks, Officer, Cristi, and Call. me Lucera, Officer, Editas Linda Officer, Editas' you Medical today Mei, for everyone. Second joining on With XXXX Chief members Chief our our Quarter X the Scientific Baisong other
leave more today's keep questions. Because and time brief going it your is to we're remarks summertime, to take prepared
with as the of programmable we that momentum previously gene with position untreatable Editas' me genetic editing. and patients a undertreated life-changing goal to and in Editas XXXX, progress Editas' by second disease in leader Let pursue to deliver as vivo to pleased or medicines start are quarter we saying
strategy. underpin pillars our Three
a gene-edited formerly cell toward to commercialization. drive as of EDIT-XXX and pillars those reni-cel, BLA known hemoglobinopathies, therapy first The is for
the The second, focus increase to IP.
At build business development a following differentiated on And announced with the very start particular we in activities monitoring objectives. our XXXX strong editing third, to Pipeline. XXXX, of the vivo a
will for cell from in the beta-thalassemia clinical the update in cohort we severe trial reni-cel, and XXXX. complete provide in sickle for continued trial EdiTHAL enrollment enrollment disease We initiate RUBY adult the For and RUBY mid-XXXX and and by year-end adolescent cohort would a EdiTHAL. transfusion-independent
leverage And vivo would proof vivo we BD, our would drive pipeline, IP editing gene portfolio value concept and development business for we in establish our preclinical undisclosed an capabilities. of complement For technology robust indication. in for core and to
Let's we this against have and with the reni-cel. in these start how executed second objectives So strategy quarter?
Annual in to clinical the included First, XX.X from European data class included continued that follow-up. best months XXXX, Association's set we shared product These sickle be will EdiTHAL RUBY clinical with EHA Hematology thalassemia data at The of data follow-up. reni-cel cell data of patients support the And beta sickle with patients XX set belief our RUBY XX.X X.X from June RUBY X months and in EdiTHAL disease. for Congress. cell a trial X.X to the data
onwards. mean from total correction of we in RUBY robust with have patients do infusion. hemoglobin X per this? the trial genders patients post XX XX% levels at with greater free And range within why hemoglobin grams think high from All deciliter. have reni-cel months So than well patients treated are and the for events level All anemia vaso-occlusive both normal a above all fetal
hospital translate of XX a for with days, which engraftment also to shorten fast demonstrate patients. mean We with stays engraftment may variability the low neutrophil
X to mean we of with a a collection, per range of apheresis have cycles cell X patient. For X
shared experience. data low EHA, slow improve clinical have the addition front with rate to rate patient with a failure burden sold process on the in recollection track redundant a continues reni-cel, to manufacturing cell the or end we This can robust that on the we cost and we and XXXX. additional for of manufacturing of year are for RUBY goods EdiTHAL Finally, failure decrease And reduce trials avoid COGS. to days this as clinical and of manufacturing by overall the cost both share
RUBY be now strong. Indeed, have adolescent the and of continues we dosing enrollment Second, to enrollment completed cohort.
quarter enrollment cohort adult this the completed we reminder, first year. of in a As the
We drug dosing concurrently. and adolescent manufacturing product adult are and scheduling
and the also We to of EdiTHAL progress cohort dose to enrollment continue completion announce adult continue to patients. pleased and are
expect our of the number duration follow-up gene conversations continued based to to the package BLA on in and our with be collaborative seen medicine we've of field. what patients, still Finally, future in FDA, we editing similar
Before I to capital use best of vivo, focused the in like also develop would are turn that and reni-cel we to to map I the on future. state very we as
frequently to focus, that the reni-cel need. towards we potential in efficiently reni-cel of patients partnering for most to drive ultimately delivered commercialization, opportunities, including part evaluate As
our on Now to targets capabilities let's vivo we in where in in strengthen pipeline, turn and therapeutic drive hematopoietic stem in discovery tissues. to and vivo lead vivo other cells continue our discovery work
by to Importantly, year. we remain preclinical proof-of-concept the in for end on of track an vivo indication establish undisclosed the
with of take in a for pipeline moment, moment vivo gene to medicines disease. to genetic rather a our take strategy want to We serious patients editing develop reiterate a
As efforts as pursuing we gene not a differentiated approach same established reminder, editing and are are the development our others. internal modalities from
our functional gene indel function First, to is of use expression of our upregulation deleterious address loss to technology strategy for or mutations.
of site. promoter functional the experimental the medicines, thus ex upregulate gene a as direct strategy in is highlighting demonstrated to gene, CRISPR that not the have it expression gene drive already we of through indel the we that is regulation, that strategy technology of worth our can leverage reni-cel, development vivo knockdown our technology our gamma-globin reni-cel. of homolog beta-globin With indel creating editing gene functional our HPGX-X And of clear, be in others pursuing. me editing are Let differentiated the
approach of as genes this now therapeutics vivo indel we same or differentiated the build using applying to our to disease in technology upregulate our functionally target by functional pipeline. are wild-type alleles We homolog
Why strategy Because functional in or competing our our matter? strategy, modalities and with by that regulation are are the strategy with does vivo existing the development knockdown used on strategies. technology not and between we other difference knockdown based companies
selection given indication orphan our diseases a best-in-class strategy rare us we or allow and will Second, targets to the for believe first be indication. that
patient expect into the larger populations future. diseases to We in move with
lead is Our targets in in therapeutic and stem cells vivo work hematopoietic other tissues. an discovery
evaluating concept. of technology. our four, improved next proof vivo evaluating One, where modifications our to for components achieve and editing in more vivo the cell a that we Three, multiple in high eco-strategy success in potency, Third, into guide editing currently our look gene Editas gene I editing sharing are with lipid enzyme later RNA. in capabilities well delivery with pipeline types, nanoparticles our of technology, our gene enable to medicines. RNA vivo. superior details delivery liver as in editing our in and outcomes general multiple as this well pipeline cargo established year with tissue is in types X positioned Two, editing AsCasXXa. gene including additional forward and of delivery main And messenger vivo multiple companies about
a review to I XXXX. for summary quarter. briefly the of items today like our financial you press few quarter opportunity I'd our for Finally, release to refer a to results take this issued for the earlier
compared Our securities were June of million million March and XX equivalents cash, of cash marketable as as $XXX $XXX to XXXX. XX,
related This the note, was research higher progression the past. will higher rate clinical than to costs this quarter accelerated slightly burn expenses, manufacturing reni-cel our to program. primarily increased related of external development our and rate you is due As to and
into license the and payable together the with and under contingent We our upfront license operating marketable Vertex annual expenses to capital expect cash our fees and near-term XXXX. cash, existing our equivalents fund agreement securities, with expenditures payment
it Before you. could must we as always, without the patients, that our to we partners caregivers, turn corporate employees, our objectives and be support achieve investigators, of not Q&A,
employees, serious With into gene execution our technology this our proud sheet, a focus, are we to our energized to patients and editing commercial-stage strong deliver from our progress editing by and diseases in company. and company drive keen evolved sharp development-stage progress medicines with genetic to and and continue platform execution a We strategy world-class differentiated and strategic of balance quarter. scientists our
Thank you very for much your interest Editas. in
We now. Thank are happy you. answer to questions
